Evidence map›Paper›PMID 35223490›Full record

ArticleFrontiers in oncology2022

Single-Nucleotide Polymorphisms in LEP and LEPR Associated With Breast Cancer Risk: Results From a Multicenter Case-Control Study in Chinese Females.

Liang Li, Xingchen Meng, Liyuan Liu, Yujuan Xiang, Fei Wang, Lixiang Yu, Fei Zhou, Chao Zheng, Wenzhong Zhou, Shude Cui and 24 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Genetic alterations inFrontiers in oncology · 2023
    Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 20 institutions in 1 country.

Liang LiDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Xingchen MengDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Liyuan LiuDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Yujuan XiangDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Fei WangDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Lixiang YuDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Fei ZhouDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Chao ZhengDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Wenzhong ZhouDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Shude CuiDepartment of Breast Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China.
Fuguo TianDepartment of Breast Surgery, Shanxi Cancer Hospital, Taiyuan, China.
Zhimin FanDepartment of Breast Surgery, The First Hospital of Jilin University, Changchun, China.
Cuizhi GengDepartment of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xuchen CaoDepartment of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Zhenlin YangDepartment of Thyroid and Breast Surgery, The First Affiliated Hospital of Binzhou Medical University, Binzhou, China.
Xiang WangDepartment of Breast Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Hong LiangDepartment of General Surgery, Linyi People's Hospital, Linyi, China.
Shu WangDepartment of Breast Disease Center, Peking University People's Hospital, Beijing, China.
Hongchuan JiangDepartment of General Surgery, Beijing Chaoyang Hospital, Beijing, China.
Xuening DuanDepartment of Breast Disease Center, Peking University First Hospital, Beijing, China.
Haibo WangDepartment of Breast Center, Qingdao University Affiliated Hospital, Qingdao, China.
Guolou LiDepartment of Breast and Thyroid Surgery, Weifang Traditional Chinese Hospital, Weifang, China.
Qitang WangDepartment of Breast Surgery, The Second Affiliated Hospital of Qingdao Medical College, Qingdao Central Hospital, Qingdao, China.
Jianguo ZhangDepartment of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Feng JinDepartment of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
Jinhai TangDepartment of General Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing, China.
Liang LiDepartment of Breast and Thyroid Surgery, Zibo Central Hospital, Zibo, China.
Shiguang ZhuDepartment of Breast Surgery, Yantai Yuhuangding Hospital, Yantai, China.
Wenshu ZuoDepartment of Breast Cancer Center, Shandong Cancer Hospital, Jinan, China.
Chunmiao YeDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Gengshen YinDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Zhongbing MaDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Shuya HuangDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Zhigang YuDepartment of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Shandong University · CNShandong Center for Disease Control and Prevention · CNSecond Hospital of Shandong University · CNCentral Hospital of Zibo · CNAffiliated Hospital of Qingdao University · CNBeijing Chaoyang Emergency Medical Center · CNBinzhou University · CNChina Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Hospital of Jilin University · CNHarbin Medical University · CNHebei Medical University · CNLinyi People's Hospital · CNNanjing Medical University · CNPeking University · CNPeking University People's Hospital · CNShandong Tumor Hospital · CNShanxi Provincial Cancer Hospital · CNTianjin Medical University Cancer Institute and Hospital · CNWeifang Chinese Medicine Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLeptin (LEP) plays a physiological role through its specific receptor (LEPR) and is involved in the occurrence and development of breast cancer. Our current study aimed at determining the influence of single-nucleotide polymorphisms (SNPs) in the genes coding for LEP and LEPR on breast cancer risk.

methodsIn the present study, 963 breast cancer cases and 953 controls were enrolled. Five SNPs of LEP and two of LEPR were chosen to evaluate the correlation of selected SNPs with breast cancer susceptibility among women in northern and eastern China. Analyses were further stratified by body mass index (BMI), waist-hip rate (WHR), estrogen receptor, and progesterone receptor status. The expression patterns of risk variant-associated genes were detected by expression quantitative trait locus (eQTL) analysis with eQTLGen and The Cancer Genome Atlas database.

resultsThere were significant differences between breast cancer cases and control groups in the menopausal status and family history of breast cancer. Two SNPs (rs1137101 and rs4655555) of the LEPR gene decreased overall breast cancer risk, and other five SNPs showed no significant association with breast cancer risk. rs1137101 (GA vs. GG; adjusted OR = 0.719, 95% CI = 0.578-0.894, p = 0.003) and rs4655555 (TT vs. AA; adjusted OR = 0.574, 95% CI = 0.377-0.873, p = 0.009) significantly decreased breast cancer risk after Bonferroni correction for multiple testing. In subgroup analyses, the GA and GA + AA genotypes of LEPR rs1137101 associated with decreased breast cancer risk in the subgroup of BMI ≤ 24 kg/m

conclusionOur study demonstrated that the polymorphisms rs1137101 and rs4655555 located in the LEPR gene decreased breast cancer risk in Chinese females, which might be a research-worthy bio-diagnostic marker and applied for early prediction and risk assessment of breast cancer.

Indexed as

breast cancer riskcase–control studyLEPRleptinsingle-nucleotide polymorphisms

Identifiers

PMID35223490
PMCPMC8866686
OpenAlexW4211070200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.